🤖 GLOBAL HEALTH OPTIMIZATION AGENT v3.0

🔬 Current Disease Focus:

Task Progress: 0%

👥 Active Problem Solvers

🌍 Experts collaborating globally

⚡ Current Task Assignment

🧬 Genetic Analysis

🔄 Matching experts to specific tasks

📊 Resource Allocation by Research Phase:

📚 Data Analysis

🧪 Experimental Design

🔬 Clinical Trials

💊 Treatment Development

Trial Search

Current Search Criteria:

Intervention: Standard of Care (Paclitaxel or topotecan or doxorubicin)

Found 11 matching trials

An uMbrella Study of BIomarker-driven Targeted Therapy In Patients With Platinum-resistant Recurrent OvariaN Cancer(AMBITION)

PHASE2

This study is a pilot study of biomarker-driven targeted therapy in patient...

Status

Unknown

Location

Seoul National University Hospital

Start Date

2018-11-26

Trial ID

NCT03699449

Treatments Being Tested

olaparib+cediranib combination therapy durvalumab + olaparib combination therapy durvalumab + chemotherapy treatment durvalumab + tremelimumab + chemotherapy treatment durvalumab + tremelimumab + paclitaxel treatment durvalumab +chemotherapy treatment

Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer

PHASE2

This randomized phase II/III trial studies how well cediranib maleate and o...

Status

Active Not Recruiting

Location

University of Alabama at Birmingham Cancer Center

Start Date

2016-05-03

Trial ID

NCT02502266

Treatments Being Tested

Cediranib Cediranib Maleate Computed Tomography Magnetic Resonance Imaging Olaparib Paclitaxel Pegylated Liposomal Doxorubicin Hydrochloride Questionnaire Administration Topotecan Topotecan Hydrochloride

Recurrent Ovarian CarcinoSarcoma Anti-pd-1 Niraparib

PHASE2

Carcinosarcomas (CS) (malignant mixed Müllerian tumors) are highly aggressi...

Status

Recruiting

Location

ICO Paul Papin

Start Date

2020-07-15

Trial ID

NCT03651206

Treatments Being Tested

Niraparib Niraparib + TSR-042 (Dostarlimab)Chemotherapy Drugs

A Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01)

PHASE3

This study specifically aims to evaluate how well mocertatug rezetecan (Mo-...

Status

Recruiting

Location

GSK Investigational Site

Start Date

2026-06-18

Trial ID

NCT07286266

Treatments Being Tested

Mocertatug rezetecan Paclitaxel Pegylated liposomal doxorubicin (PLD)Topotecan Gemcitabine Pembrolizumab Bevacizumab

Avastin Plus Chemotherapy vs. Avastin Plus Chemotherapy Guided by Cancer Stem Cell Test in Recurrent Ovarian Cancer

PHASE3

The purpose of this randomized clinical study is to confirm the utility of ...

Status

Withdrawn

Location

Univeristy of Mississippi Medical Center

Start Date

2018-08-01

Trial ID

NCT03632798

Treatments Being Tested

ChemoID assay Chemotherapy

Comparing Standard of Care Chemotherapy Treatment to the Combination of Copanlisib and Olaparib for Recurrent Platinum Resistant Ovarian Cancer That Has Progressed Through PARP Inhibitor Therapy

PHASE2

This phase II trial compares copanlisib and olaparib to standard of care ch...

Status

Withdrawn

Location

University of Colorado Hospital

Start Date

2022-06-30

Trial ID

NCT05295589

Treatments Being Tested

Computed Tomography Copanlisib Hydrochloride Magnetic Resonance Imaging Olaparib Paclitaxel Pegylated Liposomal Doxorubicin Hydrochloride Topotecan Hydrochloride

Cancer Stem Cell Assay Directed Chemotherapy in Recurrent Platinum Resistant Ovarian Cancer

PHASE3

The purpose of this clinical study is to confirm the utility of chemosensit...

Status

Active Not Recruiting

Location

Kaiser Permanente

Start Date

2019-07-26

Trial ID

NCT03949283

Treatments Being Tested

ChemoID Assay Standard Chemotherapy

A Study of PHST001 in Advanced Solid Tumors

PHASE1

This is a multi-center, first-in-human (FIH), open-label, Phase 1a/1b dose ...

Status

Recruiting

Location

Precision NextGen Oncology & Research Center

Start Date

2025-03-31

Trial ID

NCT06840886

Treatments Being Tested

PHST001 Chemotherapy per Standard of Care

Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies

PHASE1

This phase Ib trial studies the side effects and best dose of selinexor whe...

Status

Terminated

Location

MD Anderson in The Woodlands

Start Date

2015-06-26

Trial ID

NCT02419495

Treatments Being Tested

Capecitabine Carboplatin Cyclophosphamide Doxorubicin Eribulin Fluorouracil Ipilimumab Irinotecan Hydrochloride Leucovorin Calcium Nivolumab Olaparib Oxaliplatin Paclitaxel Pembrolizumab Pemetrexed Selinexor Topotecan

Efficacy of DCVAC/OvCa Plus Standard of Care in Relapsed Platinum Resistant Epithelial Ovarian Carcinoma

PHASE2

The purpose of this study is to determine whether DCVAC/OvCa added to chemo...

Status

Terminated

Location

Multiple Locations

Start Date

2014-01

Trial ID

NCT02107378

Treatments Being Tested

DCVAC/OvCa Standard of Care (Paclitaxel or topotecan or doxorubicin)

Previous Next